CAS: 144-11-6; 1-Cyclohexyl-1-Phenyl-3-Piperidin-1-Ylpropan-1-Ol

该化合物是一种合成抗胆碱基药物,主要用于治疗帕金森的疾病和药物引起的毒死性症状;它的作用是阻断肌肉受体乙酰胆碱酯酶作用,这有助于缓解颤抖和僵化等症状;该化合物的特点是其化学结构,包括一个苯基环和管状动物,有助于其药理活动;它通常口服,半衰期相对较长,每天允许服用一两次;它的潜在副作用是已知的,其中可能包括干口,模糊的视力,便秘和尿液保留,因为其抗胆碱性特性;此外,由于它有可能被滥用和副作用,它在某些管辖区被归类为受管制的物质;它的功效和安全特征使它在运动紊乱的管理中成为有价值的选择,尽管仔细监测对于减轻不利影响至关重要.

结构式图片

MSDS等安全信息

欧盟法规

REACH注册ECHA物质REACH预注册

上下游产品

CAS号73-63-2 Β-哌啶子基苯丙酮 | CAS号931-50-0 环己基溴化镁 | CAS号110-89-4 六氢吡啶 | CAS号13487-73-5 3-chloro-1-cycl... | CAS号511-45-5 二苯帕诺 | CAS号108-85-0 溴代环己烷 | CAS号108-86-1 溴苯 | CAS号19653-33-9 1-哌啶丙酸乙酯

合成工艺路线路线简述

    📜哌啶置于苯体系中,化学反应生成苯海索
    参考文献:[合成具有解痉活性的化合物.二.氨基叔醇的制备新方法]
    标题:[合成具有解痉活性的化合物.二.氨基叔醇的制备新方法]
    摘要:
    Doi:10.1002/ardp.19582910107

    海关参考信息

    专利信息


    专利号:WO-2025128098-A1
    优先权日:2023-12-13
    标 题 :Solid oral dosage forms, kits, and methods of using the same
    发明人:LI YING; LANGER ROBERT; TRAVERSO CARLO
    权利人:MASSACHUSETTS INST TECHNOLOGY; BRIGHAM & WOMENS HOSPITAL INC
    摘要:Provided herein are solid oral dosage forms, methods, and kits useful, e.g, for the extension of the residence time of active pharmaceutical agents in vivo by the synthesis of a polymer in situ in a subject. In particular, the solid oral dosage forms, methods, and kits disclosed herein are particularly useful for drugs that require more than once daily administration (e.g, drugs that have short half-lives).

    专利号:US-7273888-B2
    优先权日:2001-11-16
    标题 :Use of difluoromethylornithine (DFMO) for the treatment of amyotrophic lateral sclerosis
    发明人:RAMESH TENNORE; SCOTT SEAN
    权利人:ALS THERAPY DEV FOUNDATION INC
    摘要:The present invention provides methods and compositions for modulating polyamine pathway activity as a means for ameliorating neurodegenarative disorders. In particular, for ameliorating the symptoms or onset of amyotrophic lateral sclerosis (ALS) by modulating the gene and protein products involved the polyamine pathway, such as by inhibiting the enzyme, ornithine decarboxylase (ODC), involved in the synthesis of the polyamine, putrescine. Compositions and methods are disclosed for inhibiting the polyamine pathway producing lower polyamine levels resulting in a beneficial effect on ALS. This can be accomplished by using modulating agents such as analogs, or polyamine analogs, and antiproliferative drugs. In particular, the ODC inhibitor difuoromethylornithine (DFMO) is disclosed as a useful pharmacological agent in the modulation and treatment of ALS. Screening assays for pharmacological agents that are capable of decreasing polyamine levels and/or reducing cell proliferation are also disclosed.

    专利号:US-2009285888-A1
    优先权日:2005-05-13
    标题:Derivatives of dihydroxyphenylalanine
    发明人:SUSILO GISELA
    权利人:SUSILO GISELA
    摘要:The invention relates to derivatives of dihydroxyphenylalanine, to their synthesis and to pharmaceutical compositions containing said derivatives of dihydroxyphenylalanine. Furthermore, the invention relates to the use of said derivatives of dihydroxyphenylalanine and said pharmaceutical compositions for the treatment and prophylaxis of movement disorders, neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, hemiparkinson-hemiatrophy, parkinsonian syndrome, Lewy body disease, frontotemporal dementia, Lytico-Bodig disease (parkinsonism/dementia/amyotrophic lateral sclerosis), striatonigral degeneration, Shy-Drager syndrome, sporadic olivopontocerebellar degeneration, progressive atrophy of the globus pallidus, progressive supranuclear palsy, Hallervorden-Spatz disease, Huntington's disease, X-linked dystonia-parkinsonism (Lubag), mitochondrial cytopathy with striatal necrosis, neuroacanthocytosis, restless legs syndrome, Wilson's disease.

    专利号:US-9994558-B2
    优先权日:2013-09-20
    标题 :Multicyclic compounds and methods of using same
    发明人:BALOGLU ERKAN; SHACHAM SHARON; SENAPEDIS WILLIAM; MCCAULEY DILARA; LANDESMAN YOSEF; GOLAN GALI; KALID ORI; SHECHTER SHARON
    权利人:KARYOPHARM THERAPEUTICS INC
    摘要:The invention generally relates to compounds represented by Structural Formula I: or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in treatment of cancer (e.g., mantle cell lymphoma), and other diseases and disorders (e.g., PAK-mediated, for example, PAK4-mediated, diseases and disorders).

    专利号:US-8697888-B2
    优先权日:2012-01-06
    标题 :Substituted (1-(methylsulfonyl)azetidin-3-yl)(heterocycloalkyl)methanone analogs as antagonists of muscarinic acetylcholine M1 receptors
    发明人:LINDSLEY CRAIG W; CONN P JEFFREY; WOOD MICHAEL R; MELANCON BRUCE J; CHEUNG YIU-YIN
    权利人:UNIV VANDERBILT
    摘要:In one aspect, the invention relates to substituted (1-(methylsulfonyl)azetidin-3-yl)(heterocycloalkyl)methanone analogs, derivatives thereof, and related compounds, which are useful as antagonists of the muscarinic acetylcholine receptor M 1 (mAChR M 1 ); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

    专利号:US-9056875-B2
    优先权日:2012-08-31
    标 题 :Substituted pyrazolo[3′,4′:4,5]thieno[2,3-C]pyridazin-3-amine analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M4
    发明人:LINDSLEY CRAIG W; CONN P JEFFREY; WOOD MICHAEL R; SALOVICH JAMES M
    权利人:UNIV VANDERBILT
    摘要:In one aspect, the invention relates to substituted pyrazolo[3′,4′:4,5]thieno[2,3-c]pyridazine-3-amine analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor M 4 (mAChR M 4 ); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Mahal P, Nishanth KN, Mahapatra A, Sarkar S, Balhara YPS. Trihexyphenidyl Misuse in Delusional Disorder. J Neurosci Rural Pract. 2018 Jul-Sep;9(3):428-430. doi: 10.4103/jnrp.jnrp_569_17.
    2: Chalavi S, Fakhari AR, Nojavan S. Development of a modified partial filling method in capillary electrophoresis using two chiral plugs for the simultaneous enantioseparation of chiral drugs: Comparison with mixed chiral selector capillary electrophoresis. J Chromatogr A. 2018 Sep 14;1567:211-218. doi: 10.1016/j.chroma.2018.06.052. Epub 2018 Jun 21. Available from http://www.ncbi.nlm.nih.gov/books/NBK501671/ Available from http://www.ncbi.nlm.nih.gov/books/NBK500935/ doi: 10.1016/j.jphs.2018.05.007. Epub 2018 Jun 7. doi: 10.1097/JCP.0000000000000911. doi: 10.1002/bio.3496. Epub 2018 May 21. doi: 10.1002/14651858.CD012430.pub2. Review. doi: 10.1097/JCP.0000000000000882. doi: 10.1111/dmcn.13652. Epub 2018 Feb 6. Review. doi: 10.1017/cjn.2017.208. doi: 10.1097/MD.0000000000008711.
    14: Nadaf SN, Chakor RT, Kothari KV, Bharote H. Progressive delayed hemidystonia following clinically mild traumatic brain injury. BMJ Case Rep. 2017 Dec 28;2017. pii: bcr-2017-220334. doi: 10.1136/bcr-2017-220334. doi: 10.4103/IJPSYM.IJPSYM_380_17.

    合成参考文献


    参考文献:10.1007/s10549-011-1595-y
    摘要:Creighton CJ, Sada YH, Zhang Y, Tsimelzon A, Wong H, Dave B, Landis MD, Bear HD, Rodriguez A, Chang JC. A gene transcription signature of obesity in breast cancer. Breast Cancer Research and Treatment. 2011 Jul 13;132(3):993–1000. doi: 10.1007/s10549-011-1595-y.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知